M&I's MabCampath is approved by EMEA

11 July 2001

Millennium & ILEX Partners, the joint venture between MillenniumPharmaceuticals and ILEX Oncology, has been granted authorization by the European Medicines Evaluation Agency to market MabCampath (alemtuzumab), its humanized monoclonal antibody for patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating drugs and have failed fludarabine therapy. MabCampath will be marketed in Europe by Schering AG.

The antibody was launched in the USA in May, as Campath, by Schering's US affiliate Berlex Laboratories (Marketletter May 21). M&I has said it is now starting a post-approval clinical trial of MabCampath versus chlorambucil, the standard first-line treatment for B-CLL.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight